Key Takeaways:
BioMarin Pharmaceutical Inc.’s (BMRN) experimental drug for a rare genetic bone disease failed to show a clinical benefit in a pivotal trial, casting doubt on the program’s future and sending its shares down 2.7 percent. While BMN 401 met one of two primary goals by significantly increasing a key blood biomarker, it didn't improve rickets severity in children with ENPP1 deficiency.
"We are disappointed that the significant increases in plasma PPi observed with BMN 401 did not translate into meaningful clinical improvements for children with ENPP1 deficiency," Greg Friberg, BioMarin’s chief research and development officer, said in a statement. "We are actively evaluating these data to determine the appropriate next steps."
The Phase 3 ENERGY 3 study, which enrolled 27 children aged 1 to 12, showed that treatment with BMN 401 led to a statistically significant rise in plasma inorganic pyrophosphate (PPi) levels. However, the trial missed its other co-primary endpoint, the Radiographic Global Impression of Change (RGI-C) score, a key measure of rickets improvement. No positive trends were seen in secondary goals like Rickets Severity Score or growth.
The failure is a setback for BioMarin’s rare disease pipeline, a key focus for the $10 billion company. ENPP1 deficiency is a devastating condition with a high mortality rate in infants, representing a significant unmet need. Investors will now watch for whether BioMarin abandons the BMN 401 program or attempts another costly trial, with shares already trading down nearly 13 percent year-to-date.
BMN 401, a subcutaneous enzyme replacement therapy, was designed to correct the deficiency of the ENPP1 enzyme, which leads to low levels of PPi. This deficiency causes progressive damage to bones, blood vessels, and soft tissues. The trial results create a challenging situation for BioMarin: the drug successfully targeted the underlying biomarker it was designed to fix, but that biochemical change had no apparent effect on the clinical symptoms of the disease in children.
ENPP1 deficiency manifests as generalized arterial calcification of infancy (GACI) Type 1 in infants, a condition where about half of patients die within six months. In children, it typically causes a form of rickets known as autosomal-recessive hypophosphatemic rickets type 2 (ARHR2), leading to softened bones, pain, and difficulty moving.
BioMarin has not yet disclosed its cash runway for the program. The company stated it will present detailed results from the ENERGY 3 study at an upcoming medical meeting. The decision on whether to continue investing in BMN 401 will be closely watched. While the market for ENPP1 deficiency is small, successful rare disease drugs can command high prices and become significant revenue drivers. The mixed trial results, however, significantly raise the bar for regulatory approval and commercial viability.
The market reaction was specific to BioMarin, with the stock’s 2.7% decline standing out against more modest moves from biotech peers like BridgeBio Pharma Inc. (BBIO) and Ionis Pharmaceuticals Inc. (IONS).
This article is for informational purposes only and does not constitute investment advice.
